TVRD Tvardi Therapeutics, Inc.

NASDAQ
$1.27

Tvardi Therapeutics, Inc. (TVRD) is expected to report earnings on November 13, 2026, before the market open. The consensus earnings estimate is a loss of $0.51 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -29.8% since its last earnings release on August 14, 2026.

Tvardi Therapeutics Missed Consensus Estimates
Friday, August 14, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 13
Friday · 7:00 AM ET
Earnings Whisper
-
vs ($0.51)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.76

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Tvardi Therapeutics, Inc.

Tvardi Therapeutics Inc. is a privately held, clinical-stage, biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Tvardi Therapeutics Inc., formerly known as Cara Therapeutics Inc., is based in STAMFORD, Conn.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.